Aldeyra's Dry Eye Drug Application Denied by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy ALDX?
Source: PRnewswire
- FDA Rejection: On March 17, 2026, Aldeyra Therapeutics received a Complete Response Letter from the FDA indicating that its New Drug Application for dry eye treatment lacked sufficient evidence of efficacy, severely undermining investor confidence.
- Stock Price Plunge: Following the FDA's rejection, Aldeyra's stock price fell by $2.99, a staggering 70.69% drop, closing at $1.24, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Aldeyra and its executives engaged in securities fraud or other unlawful business practices, which could lead to legal liabilities and further impact shareholder interests.
- Historical Context: Founded over 85 years ago, Pomerantz LLP specializes in securities class actions and has recovered millions in damages for victims, demonstrating its strong capability in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.680
Low
9.00
Averages
9.50
High
10.00
Current: 1.680
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aldeyra Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised Aldeyra Therapeutics investors of a class action for those who purchased securities between November 3, 2023, and March 16, 2026, with a deadline of May 29, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Inconsistent Clinical Trial Results: The complaint alleges that Aldeyra failed to disclose the inconsistency of reproxalap clinical trial results during the class period, rendering any positive findings unreliable and making the company's statements about its business and prospects materially false and misleading at all relevant times.
- Regulatory Letter Impact: On March 17, 2026, Aldeyra filed an 8-K report with the SEC announcing receipt of the 2026 Complete Response Letter, which stated a lack of substantial evidence supporting the drug's efficacy, leading to a significant loss of investor confidence.
- Stock Price Plunge: Following this news, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
See More
Aldeyra Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Gainey McKenna & Egleston has initiated a securities class action lawsuit in the U.S. District Court for Massachusetts on behalf of all investors who acquired Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, indicating significant investor dissatisfaction with the company's transparency.
- Inconsistent Clinical Trial Results: The complaint alleges that defendants failed to disclose the inconsistency of reproxalap clinical trial results, which rendered any positive findings unreliable, thereby materially misleading investors about the company's business prospects and operations.
- Stock Price Plummet: Following the disclosure of these alleged failures, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share on March 17, 2026, directly causing substantial losses for investors and reflecting a sharp decline in market trust in the company.
- Investor Rights Protection: Investors are urged to contact the law firm before the May 29, 2026, lead plaintiff motion deadline to ensure their rights are effectively represented in the class action, highlighting the importance of legal processes in safeguarding investor interests.
See More
Aldeyra Therapeutics Faces Securities Fraud Lawsuit
- Stock Price Plunge: Aldeyra Therapeutics' shares plummeted over 65% on March 17, 2026, after the company disclosed receiving a Complete Response Letter from the FDA regarding reproxalap for dry eye disease, indicating the drug failed to demonstrate efficacy in adequate clinical trials, severely undermining investor confidence.
- Lawsuit Initiation: Block & Leviton has filed a securities fraud lawsuit against Aldeyra Therapeutics and certain executives, allowing affected investors to contact the firm to explore recovery options, highlighting significant concerns regarding corporate governance and transparency among investors.
- FDA Feedback Impact: The FDA previously indicated on April 3, 2025, that the reproxalap application did not demonstrate efficacy in adequately controlled studies for treating dry eye symptoms, necessitating at least one additional study to validate effectiveness, thereby increasing future R&D pressures on the company.
- Investor Action Recommendation: Investors must seek lead plaintiff status by May 29, 2026, or risk remaining absent class members, emphasizing the critical importance of timely action in legal proceedings to safeguard their rights.
See More
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, indicating a risk-free legal avenue for victims and potentially attracting more investors to seek justice.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
- Case Details Revealed: The lawsuit claims that Aldeyra's drug candidate reproxalap had inconsistent clinical trial results, rendering the company's statements about its business prospects materially false and misleading, which could have long-term implications for investor confidence.
See More
Aldeyra Therapeutics Faces Securities Investigation
- Investigation Launched: Rosen Law Firm has announced an investigation into Aldeyra Therapeutics (NASDAQ: ALDX) for potential securities claims due to allegations of issuing materially misleading business information, which has negatively impacted investor confidence.
- Stock Price Plunge: On March 17, 2026, Aldeyra's stock price fell by $2.99, or 70.7%, closing at $1.24 per share after receiving a Complete Response Letter (CRL) from the FDA, indicating serious concerns about the efficacy of its new drug application.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees, highlighting the firm's commitment to protecting investor rights.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Rosen Law Firm Investigates Aldeyra Securities Claims
- Securities Claims Investigation: Rosen Law Firm announces an investigation into Aldeyra Therapeutics, Inc. for potentially issuing materially misleading business information, which may have adversely affected investor decisions.
- FDA Response Letter: In a report filed with the SEC on March 17, 2026, Aldeyra disclosed that the FDA's Complete Response Letter indicated a lack of substantial evidence to support the efficacy of its drug for dry eye disease, undermining investor confidence.
- Stock Price Plunge: Following this news, Aldeyra's stock price plummeted by $2.99, a staggering 70.7% drop, closing at $1.24 per share, reflecting extreme market pessimism regarding its future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate in claims without upfront costs, highlighting the firm's commitment to protecting investor rights.
See More
Aldeyra Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised Aldeyra Therapeutics investors of a class action for those who purchased securities between November 3, 2023, and March 16, 2026, with a deadline of May 29, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Inconsistent Clinical Trial Results: The complaint alleges that Aldeyra failed to disclose the inconsistency of reproxalap clinical trial results during the class period, rendering any positive findings unreliable and making the company's statements about its business and prospects materially false and misleading at all relevant times.
- Regulatory Letter Impact: On March 17, 2026, Aldeyra filed an 8-K report with the SEC announcing receipt of the 2026 Complete Response Letter, which stated a lack of substantial evidence supporting the drug's efficacy, leading to a significant loss of investor confidence.
- Stock Price Plunge: Following this news, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
See More
Aldeyra Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Gainey McKenna & Egleston has initiated a securities class action lawsuit in the U.S. District Court for Massachusetts on behalf of all investors who acquired Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, indicating significant investor dissatisfaction with the company's transparency.
- Inconsistent Clinical Trial Results: The complaint alleges that defendants failed to disclose the inconsistency of reproxalap clinical trial results, which rendered any positive findings unreliable, thereby materially misleading investors about the company's business prospects and operations.
- Stock Price Plummet: Following the disclosure of these alleged failures, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share on March 17, 2026, directly causing substantial losses for investors and reflecting a sharp decline in market trust in the company.
- Investor Rights Protection: Investors are urged to contact the law firm before the May 29, 2026, lead plaintiff motion deadline to ensure their rights are effectively represented in the class action, highlighting the importance of legal processes in safeguarding investor interests.
See More
Aldeyra Therapeutics Faces Securities Fraud Lawsuit
- Stock Price Plunge: Aldeyra Therapeutics' shares plummeted over 65% on March 17, 2026, after the company disclosed receiving a Complete Response Letter from the FDA regarding reproxalap for dry eye disease, indicating the drug failed to demonstrate efficacy in adequate clinical trials, severely undermining investor confidence.
- Lawsuit Initiation: Block & Leviton has filed a securities fraud lawsuit against Aldeyra Therapeutics and certain executives, allowing affected investors to contact the firm to explore recovery options, highlighting significant concerns regarding corporate governance and transparency among investors.
- FDA Feedback Impact: The FDA previously indicated on April 3, 2025, that the reproxalap application did not demonstrate efficacy in adequately controlled studies for treating dry eye symptoms, necessitating at least one additional study to validate effectiveness, thereby increasing future R&D pressures on the company.
- Investor Action Recommendation: Investors must seek lead plaintiff status by May 29, 2026, or risk remaining absent class members, emphasizing the critical importance of timely action in legal proceedings to safeguard their rights.
See More
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, indicating a risk-free legal avenue for victims and potentially attracting more investors to seek justice.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
- Case Details Revealed: The lawsuit claims that Aldeyra's drug candidate reproxalap had inconsistent clinical trial results, rendering the company's statements about its business prospects materially false and misleading, which could have long-term implications for investor confidence.
See More
Aldeyra Therapeutics Faces Securities Investigation
- Investigation Launched: Rosen Law Firm has announced an investigation into Aldeyra Therapeutics (NASDAQ: ALDX) for potential securities claims due to allegations of issuing materially misleading business information, which has negatively impacted investor confidence.
- Stock Price Plunge: On March 17, 2026, Aldeyra's stock price fell by $2.99, or 70.7%, closing at $1.24 per share after receiving a Complete Response Letter (CRL) from the FDA, indicating serious concerns about the efficacy of its new drug application.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees, highlighting the firm's commitment to protecting investor rights.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Rosen Law Firm Investigates Aldeyra Securities Claims
- Securities Claims Investigation: Rosen Law Firm announces an investigation into Aldeyra Therapeutics, Inc. for potentially issuing materially misleading business information, which may have adversely affected investor decisions.
- FDA Response Letter: In a report filed with the SEC on March 17, 2026, Aldeyra disclosed that the FDA's Complete Response Letter indicated a lack of substantial evidence to support the efficacy of its drug for dry eye disease, undermining investor confidence.
- Stock Price Plunge: Following this news, Aldeyra's stock price plummeted by $2.99, a staggering 70.7% drop, closing at $1.24 per share, reflecting extreme market pessimism regarding its future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate in claims without upfront costs, highlighting the firm's commitment to protecting investor rights.
See More
